Jan 21, 2021 7:00am EST Sutro Biopharma Announces First Patient Dosed in the Dose-Expansion Study of STRO-002 in Patients with Ovarian Cancer
Jan 05, 2021 7:00am EST Sutro Biopharma to Present at the 39th Annual J.P. Morgan Virtual Healthcare Conference
Dec 11, 2020 4:01pm EST Sutro Biopharma Announces Closing of Upsized $144.9 Million Public Offering, including Full Exercise of the Underwriters' Option to Purchase Additional Shares
Dec 07, 2020 4:00pm EST Sutro Biopharma Announces Proposed Public Offering of 5 Million Shares of Common Stock
Dec 07, 2020 10:00am EST Sutro Biopharma Presents Data from Ongoing Phase 1 Dose-Escalation Study for STRO-001 for the Treatment of B-cell Non-Hodgkin Lymphoma at the 62nd American Society of Hematology Annual Meeting
Dec 03, 2020 4:30pm EST Sutro Biopharma Announces Encouraging Interim Data on STRO-002 Phase 1 Dose-Escalation Study for Patients with Ovarian Cancer
Dec 01, 2020 7:00am EST Sutro Biopharma Announces Appointment of Jon M. Wigginton, M.D., to Board of Directors
Nov 24, 2020 7:00am EST Sutro Biopharma to Host a Virtual KOL Event to Provide Clinical Update on Antibody-Drug Conjugate STRO-002 in Ovarian Cancer
Nov 18, 2020 7:00am EST Sutro Biopharma Announces the Appointment of Diana Landa as Vice President of Regulatory Affairs and Annie Chang as Head of Investor Relations
